- Home
- NRSN vs STTK Comparison
NRSN vs STTK Comparison
Compare NRSN & STTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NRSN
- STTK
- Stock Information
- Founded
- NRSN 2017
- STTK 2016
- Country
- NRSN Israel
- STTK United States
- Employees
- NRSN N/A
- STTK N/A
- Industry
- NRSN Biotechnology: Pharmaceutical Preparations
- STTK Biotechnology: Pharmaceutical Preparations
- Sector
- NRSN Health Care
- STTK Health Care
- Exchange
- NRSN Nasdaq
- STTK Nasdaq
- Market Cap
- NRSN 37.9M
- STTK 37.6M
- IPO Year
- NRSN 2021
- STTK 2020
- Fundamental
- Price
- NRSN $1.79
- STTK $1.14
- Analyst Decision
- NRSN Buy
- STTK Hold
- Analyst Count
- NRSN 2
- STTK 4
- Target Price
- NRSN $14.00
- STTK $3.00
- AVG Volume (30 Days)
- NRSN 297.9K
- STTK 101.1K
- Earning Date
- NRSN 06-23-2025
- STTK 07-31-2025
- Dividend Yield
- NRSN N/A
- STTK N/A
- EPS Growth
- NRSN N/A
- STTK N/A
- EPS
- NRSN N/A
- STTK N/A
- Revenue
- NRSN N/A
- STTK $4,606,000.00
- Revenue This Year
- NRSN N/A
- STTK N/A
- Revenue Next Year
- NRSN N/A
- STTK N/A
- P/E Ratio
- NRSN N/A
- STTK N/A
- Revenue Growth
- NRSN N/A
- STTK 69.65
- 52 Week Low
- NRSN $0.51
- STTK $0.69
- 52 Week High
- NRSN $1.80
- STTK $7.49
- Technical
- Relative Strength Index (RSI)
- NRSN 73.77
- STTK 56.02
- Support Level
- NRSN $1.65
- STTK $0.98
- Resistance Level
- NRSN $1.77
- STTK $1.13
- Average True Range (ATR)
- NRSN 0.14
- STTK 0.10
- MACD
- NRSN 0.02
- STTK 0.01
- Stochastic Oscillator
- NRSN 100.00
- STTK 84.85
About NRSN NeuroSense Therapeutics Ltd.
NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. These diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease, and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release or ER, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.
About STTK Shattuck Labs Inc.
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.